MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics

— Milestone Achieved Through Growing Clinical Evidence Demonstrating Real-World Impact on Infection Management —

— MeMed and Physicians Premier Celebrated Milestone Event in Corpus Christi, Texas —

MeMed, a global leader in host-response diagnostics, today announced a major milestone: more than 100,000 patients have now been tested with MeMed BV^®, the company’s flagship diagnostic that accurately distinguishes between bacterial and viral infections in just 15 minutes, based on the body’s immune response. This milestone highlights MeMed’s commitment to advancing precision medicine, empowering responsible antibiotic use by care providers, and transforming infection management across diverse care settings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605939972/en/

MeMed celebrates global clinical milestone for MeMed BV test with Physicians Premier ER. From left to right: Teri Cardenas, CEO, Physicians Premier ER; Tal Avziz, VP, Global Marketing, MeMed; Dr. Annie Quysner, CMO, Physicians Premier ER; Dr. David Kenyon, Governing Board Member and Founder, Physicians Premier ER; Allison Apple, CNO, Physicians Premier ER.

Advancing Antibiotic Stewardship and Clinical Decision-Making

The growing adoption of MeMed BV in emergency medicine, urgent care, and hospital settings indicates the industry's move toward host-response and precision diagnostics. From hospital systems to decentralized care providers, MeMed BV has been integrated into real-world clinical workflows by clinicians committed to improving patient outcomes.

Among these trailblazing partners is Physicians Premier, an innovative network of freestanding emergency rooms that has embraced MeMed BV as part of its commitment to advanced, patient-centered care. The 100,000th patient test was performed at Physicians Premier’s Parkdale clinic in Corpus Christi, Texas, a symbolic moment that was marked with a joint celebration between MeMed and Physicians Premier leadership earlier today.

“At Physicians Premier, we are committed to delivering cutting edge, personalized care that prioritizes both patient well-being and best practices,” said Teri Cardenas, CEO of Physicians Premier. “MeMed BV has empowered our clinicians to make more informed decisions, reducing unnecessary antibiotic prescriptions while improving patient outcomes. We are proud to stand with MeMed at the forefront of diagnostic innovation.”

Scaling Global Impact through Strategic Partnerships

The 100,000-test milestone represents broader industry shifts toward rapid host-response diagnostics and underscores MeMed's global growth strategy. The company remains focused on scaling through partnerships with decentralized and hospital-based providers, integrating high-throughput analyzers to serve acute care settings, and collaborating on distribution agreements across the U.S., Europe, and emerging markets.

“Crossing the 100,000-patient mark is more than a milestone—it’s a meaningful indicator of the clinical value we’re delivering,” said Eran Eden, Ph.D., Co-Founder and CEO of MeMed. “It reflects the trust of a growing network of forward-thinking healthcare partners like Physicians Premier, as we jointly transform the landscape of infectious disease management. With only a fraction of the potential market reached—and backed by strong clinical evidence and strategic partnerships—we anticipate accelerating momentum, bringing critical answers to clinicians and patients when they matter most.”

MeMed continues to engage healthcare providers and industry leaders to advance adoption of rapid, reliable diagnostics that improve patient care.

About MeMed

At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

MeMed BV^® is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes.

MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to aid early risk assessment in ED patients with suspected infection or sepsis. It predicts severe outcomes within 72 hours and mortality within 14 days. MeMed Severity is not yet cleared for sale in any territory.

Follow and connect with MeMed via LinkedIn, Twitter/X, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250605939972/en/

@memeddx Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics